Madrigal (MDGL) CMO granted stock options and RSUs with multi‑year vesting

Rhea-AI Filing Summary

Madrigal Pharmaceuticals Chief Medical Officer David Soergel received new equity awards in the form of stock options and restricted stock units. On March 4, 2026, he was granted options for 5,467 shares at an exercise price of $0.00 per share and 4,374 shares of common stock as a restricted stock unit award.

The restricted stock units vest in four equal installments of 25% on March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, if he remains in service on each date. The option vests 25% on March 4, 2027, with an additional 6.25% vesting on the last day of each successive three‑month period, also subject to continued service. Following these grants, he directly holds 11,919 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Soergel David

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	5,467	$0.00	--
Grant/Award	Common Stock	4,374	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 5,467 shares (Direct); Common Stock — 11,919 shares (Direct)

Footnotes (1)

1. Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date. The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Soergel David

(Last) (First) (Middle)

C/O MADRIGAL PHARMACEUTICALS, INC.

200 BARR HARBOR DRIVE, SUITE 200

(Street)

WEST CONSHOHOCKEN PA 19428

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A(1)		4,374	A	$0	11,919	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$434.8	03/04/2026		A		5,467		(2)	03/04/2036	Common Stock	5,467	$0	5,467	D

Explanation of Responses:

1. Represents a grant of restricted stock units, which vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030, provided the Reporting Person continues in service with the Issuer on each such date.

2. The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Remarks:

	/s/ Mardi Dier, as Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Madrigal Pharmaceuticals (MDGL) CMO David Soergel acquire in this Form 4?

David Soergel received a stock option for 5,467 shares and a restricted stock unit award covering 4,374 shares of Madrigal common stock. Both grants were made on March 4, 2026 as part of his equity compensation package, with future vesting tied to continued service.

How do the restricted stock units granted to MDGL’s CMO vest over time?

The 4,374 restricted stock units vest in four equal 25% installments on March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030. Each vesting date requires that David Soergel continues in service with Madrigal Pharmaceuticals through that specific date.

What is the vesting schedule for the 5,467 Madrigal Pharmaceuticals stock options?

The option vests 25% of the 5,467 shares on March 4, 2027, the first anniversary of grant. Thereafter, 6.25% of the shares vest on the last day of each successive three‑month period, conditioned on David Soergel remaining in service with Madrigal on each vesting date.

What is David Soergel’s Madrigal Pharmaceuticals share ownership after these grants?

After the March 4, 2026 grants, David Soergel directly holds 11,919 shares of Madrigal common stock. This total reflects his non‑derivative ownership following the restricted stock unit award reported in the Form 4, separate from his newly granted stock options.

Is there a purchase price on the new stock options reported for MDGL’s CMO?

The stock option grant covering 5,467 Madrigal shares is reported with a transaction price of $0.00 per share. This reflects that the award was a compensatory grant, not an open‑market purchase, subject to its stated vesting schedule and service conditions.

Are the Madrigal Pharmaceuticals equity awards to the CMO subject to continued employment?

Yes. Both the restricted stock units and stock options vest only if David Soergel continues in service with Madrigal on each relevant vesting date. Missing a vesting date due to ending service would prevent unvested portions from becoming earned under the disclosed terms.